MedTech Archives - Page 2 of 10

International Medical and Healthcare Week Highlights Hong Kong’s Strengths in Medical and Innovation

– Asia Summit on Global Health and Medical and Healthcare Fair run concurrently

– The 5th Asia Summit on Global Health launches new Silver Health Chapter, focusing on innovations in anti-ageing and enhancing healthcare for the elderly.
– The 16th Hong Kong International Medical and Healthcare Fair serves as a comprehensive platform to foster global collaborations, attracting some 300 exhibitors to showcase cutting-edge medical technologies, gerontechnology and green solutions.

The fourth International Healthcare Week (IHW), coordinated by the Hong Kong Trade Development Council (HKTDC), will take place from 26 May to 15 June. The IHW’s flagship events, the Asia Summit on Global Health (ASGH), jointly organised by the HKSAR Government and HKTDC, will be held at the Hong Kong Convention and Exhibition Centre (HKCEC) on 26 and 27 May while the Hong Kong International Medical and Healthcare Fair (Medical Fair), organised by the HKTDC and co-organised by the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA), will run concurrently from 26 to 28 May, highlighting Hong Kong’s position as a leading regional healthcare hub.

Margaret Fong, Executive Director of the HKTDC, said: “As a global hub for medical innovation, Hong Kong serves as both a ‘super-connector’ and a ‘super value-adder’, driving regional collaboration to advance healthcare innovation and foster new quality productivity in biopharmaceutical technologies. At the same time, there are pressing global public health challenges, such as an ageing population and the rising prevalence of chronic diseases, which are intensifying healthcare demand. To address these challenges, the industry is actively embracing innovative technologies to upgrade and transform the healthcare sector. This year’s ASGH introduces a dedicated Silver Health Chapter, with both ASGH and the Medical Fair highlighting healthy ageing and elderly health innovations. The HKTDC will continue to serve as a platform for cross-sector collaboration supporting industry-academia-research partnership in fields including biotechnology, digital healthcare, and smart elderly wellness. We look forward to bringing together local and global experts, investors, enterprises, and institutions through ASGH and Medical Fair, injecting new vitality into the Asian healthcare industry and shaping the future of the medical sector.”

Global expertise shapes the future of healthcare
Themed Fostering Global Collaboration for a Shared Future, the 5th ASGH reaffirms Hong Kong’s pivotal role as a leading MedTech hub in the region. Through diverse elements such as the ASGH Business Hub, ASGH connects global healthcare innovators, investors, and project owners on a single platform, acting as a catalyst for potential partnerships. Government officials and organisations, research pioneers, investors, and business leaders from the global healthcare sector will also share insights on industry trends and explore collaboration opportunities among Hong Kong, Mainland China, and global enterprises in healthcare investment and innovation.

Dr Peter K N Lam, Chairman of the HKTDC, will deliver welcome remarks, while John Lee, Chief Executive of the HKSAR will give opening remarks, and Prof Cao Xuetao, Vice-Minister of the National Health Commission of the People’s Republic of China, will give special remarks on the first day of ASGH.

The first session of the ASGH Plenary Sessions will commence on the opening day and focus on building a more equitable and sustainable healthcare system and explore how innovative policymaking and strengthened international collaboration can foster healthcare systems that are both resilient and inclusive to address emerging global health challenges. Prof Lo Chung-mau, HKSAR Government’s Secretary for Health, will deliver the special remarks and will be joined by an esteemed panel of speakers, including Prof Tsui Lap-chee, Chairman of the University of Hong Kong Foundation for Educational Development and Research; Prof Nancy Ip, President of the Hong Kong University of Science and Technology; Mr Frédéric Rimattei, Special Envoy for International Affairs of the President of French University Hospitals National Association; Dr Wu Xiaobin, Vice President of China Pharmaceutical Innovation and Research Development Association; and Mr Martin Taylor, Representative to China of World Health Organisation.

At the second plenary, speakers will examine how global stakeholders can collaborate to navigate the current economic and healthcare innovation landscape while identifying new investment and market opportunities in the health sector. The session will be chaired by Mr Victor Chu, Chairman & CEO of First Eastern Investment Group, featuring Ambassador George Hara, Group Chairman and CEO of DEFTA Partners; Prof Ng Siew-chien, Croucher Professor in Medical Sciences and Associate Dean (Research) of Faculty of Medicine of the Chinese University of Hong Kong; Dr Hiroaki Ueno, Representative Director of Mitsubishi Tanabe Pharma Corporation and Dr Prem Kumar Nair, Group Chief Executive Officer of IHH Healthcare Berhad.

During the Dialogue with Global Pioneer in Health session, Prof John Hardy, Chair of Molecular Biology of Neurological Disease of UCL Queen Square Institute of Neurology, will share his insights on his groundbreaking work on emerging therapeutic approaches to neurodegenerative diseases. Prof Hardy was awarded the Breakthrough Prize and received the Brain Prize for “groundbreaking research on the basis of Alzheimer’s disease”.

Inaugural Silver Health Chapter: Navigating ageing’s challenges & opportunities
Amidst the global demographic shift toward ageing populations, this year’s ASGH proudly inaugurates a dedicated “Silver Health Chapter” aimed at critically examining the multifaceted challenges and transformative opportunities presented by ageing societies. On the second day, a session titled Surfing the Silver Tsunami: Advancements in Geriatrics and Longevity Technology, will bring together experts including Prof Jean Woo, Director of CUHK Jockey Club Institute of Ageing of the Chinese University of Hong Kong; Dr Donald Li, Chairman of Elderly Commission; Dr Alexandra Bause, Co-Founder & Venture Partner of Apollo Health Ventures; Mr Olivier Dessajan, General Manager of China Merchants Colisée; Prof James L. Kirkland, Director of Center for Advanced Gerotherapeutics of Cedars-Sinai; and Dr Sanja Tomovska, Founder and CEO of Quant Biomarkers. This distinguished assembly will present groundbreaking developments in geroscience, while critically evaluating emerging investment paradigms within the global longevity economy.

On the same day, global industry leaders will convene for a dedicated session titled The Next Wave of Innovations in Neuroscience, examining cutting-edge advancements and emerging trends in neurological science, including novel therapeutic approaches for Parkinson’s disease and related disorders. Concurrently, the InnoHealth Showcase will feature healthcare investment projects specifically designed to address the needs of ageing populations, presenting data-driven approaches to mitigate the challenges of demographic ageing.

During ASGH, Ms Anita Ou, Managing Director and Head of Enterprise Banking of HSBC; Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong; Prof Zhang Weixiong, Associate Director of Academy for Interdisciplinary Research (PAIR) of The Hong Kong Polytechnic University; Dr Sarah Salvilla, Group Chief Health Officer of FWD Group, will share their insights on achieving “Healthy China 2030,” the high quality development of the healthcare industry, data-driven healthcare, and new collaborative models for the healthcare sector. ASGH will also address trending topics in the healthcare industry, including the prospects of gene and cell therapies, women’s health, the convergence of Chinese and Western medicine, cancer treatment, orphan drugs, and rare diseases.

ASGH, in collaboration with the Hong Kong University of Science and Technology, will host two sessions under the overarching theme “Shaping the Future of Healthcare”. These sessions will focus on the potential of artificial intelligence in the medical field and how innovative technologies can drive breakthroughs in healthcare. Featured speakers include Dr Alex Ng, President of Tencent Healthcare; Prof Graham Cooke, Vice-Dean (Research) of the Faculty of Medicine of Imperial College London; Prof Chen Hao and Prof Bonnie Zhu, Assistant Professors of the Hong Kong University of Science and Technology.

ASGH deal-making bridges investors and project owners
The ASGH deal-making facilitates one-on-one meetings both online and offline, aiming to connect investors and projects in the healthcare sector from around the world to promote global collaborations. Participating investors represent a diverse range of backgrounds, including angel investors, venture capital, corporate venture capital, private equity, family offices and more. Investment interests span pharmaceuticals, medical devices and diagnostics, AI and digital health, and community health and wellness.

The ASGH Business Hub features more than 170 innovative technology companies from 13 countries and regions, including dedicated pavilions from the mainland (Shanghai and Xiamen), Australia, and Thailand. The InnoHealth Showcase area highlights more than 70 healthcare start-ups and projects, many of which have received awards, and is led by the Innovation and Technology Commission in collaboration with six local universities and Cyberport.

Medical Fair facilitates industry collaboration
Themed as the Innovations Boosting Smart Health Experience, the 16th Medical Fair will be held from 26 to 28 May, and welcomes some 300 exhibitors from 13 countries and regions. In addition to pavilions and exhibitors from Hong Kong, Mainland China, Taiwan, Japan, Korea and Hungary, there are also pavilions from Israel, Thailand, and the United Kingdom participating for the first time, along with debut exhibitors from Germany, Italy, Luxembourg and Singapore..

The Medical Fair serves as an excellent platform for professionals worldwide, encompassing research and development institutions, manufacturers, public healthcare organisations, hospitals, clinics, distributors, and healthcare practitioners. This event facilitates the establishment of global business connections and provides valuable insights into the latest trends in the healthcare industry. The exhibition features the HKMHDIA Pavilion, as well as Biotechnology, Hospital Equipment, Rehabilitation and Elderly Care Products, and Startup zones.

This year’s Medical Fair highlights three major areas: cutting-edge medical technologies, gerontechnology, and green solutions, featuring the latest medical health devices, products, and applications, with a particular emphasis on medical diagnostics, innovations in smart hospitals, and digital health solutions.

One exhibitor will showcase a solution that uses advanced computer vision and artificial intelligence to analyse data from patients with facial paralysis and swallowing difficulties. By matching patients with the most suitable rehabilitation programmes from a database of more than 400 training exercises, the solution provides therapists personalised treatment suggestions to refine and adopt. Another exhibitor introduces medical-grade digital therapy solutions for cognitive impairments, leveraging AI to assess patient conditions and deliver customised rehabilitation programs. Further innovations include a handheld medical device for cervical examinations, which analyses cervical tissue to aid in the detection and prevention of preterm births.

The Hong Kong Council of Social Service will make its inaugural participation at the Medical Fair, presenting age-friendly technologies and products including rehabilitation and mobility aids, cognitive impairment support systems, and smart home innovations. Additionally, other exhibitors will showcase sustainable products, such as eco-conscious eating bibs crafted from recycled plastic bottles and biodegradable medical trays.

The Medical Fair features a strong line-up of leading research and academic institutions, including seven local universities, over 30 innovative technology companies at the Hong Kong Science and Technology Parks Corporation (HKSTP) pavilion, and more than 20 medical enterprises brought by the Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA). The event will actively promote innovation and collaboration across government, industry, academia, research and investment sectors.

Multiple activities will be held during the Medical Fair to help industry professionals expand their knowledge of the latest market information. The HKMHDIA Medical Fair Forum themed “The MedTech Nexus of the Greater Bay Area” features industry experts sharing their insights on topics such as intellectual property protection strategies for biomedical innovation, cross-border financial solutions for medical enterprises, the development of cross-border health data, and successful experiences in promoting medical technology in the Greater Bay Area.

“The Latest Development of Regulatory Collaboration on Medical Devices in the Greater Bay Area” seminar will bring together representatives from the Greater Bay Area Center for Medical Device Evaluation and Inspection of the National Medical Products Administration, the Department of Health, and industry leaders to discuss the latest developments, administrative systems, and regulations.

Using the HKTDC EXHIBITION+ hybrid model, the physical fair from 26 to 28 May is complemented by the Click2Match smart business matching platform, via which buyers can extend their sourcing journey from 19 May to 4 June.

Aside from ASGH and the Medical Fair, IHW also features the Hospital Authority Convention, among many other industry events.

Websites
International Healthcare Week: https://internationalhealthcareweek.hktdc.com/en

Asia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/en
Programme: https://www.asiasummitglobalhealth.com/conference/asgh/en/programme
Speakers: https://www.asiasummitglobalhealth.com/conference/asgh/en/speaker

Hong Kong International Medical and Healthcare Fair:
https://www.hktdc.com/event/hkmedicalfair/en
List of products: https://www.hktdc.com/event/hkmedicalfair/en/product
Activity schedule: https://www.hktdc.com/event/hkmedicalfair/en/intelligence-hub

Members of the media interested in interviewing ASGH speakers, please send requests to tleung@yuantung.com.hk on or before 20 May 2025

Media enquiries
For enquiries, please contact Yuan Tung Financial Relations Limited:

Louise Song	Tel: (852) 3428 5691	Email: lsong@yuantung.com.hk
Tiffany Leung	Tel: (852) 3428 2361	Email: tleung@yuantung.com.hk

HKTDC’s Communications & Public Affairs Department:
Asia Summit on Global Health

Sharon Ha	Tel: (852) 2584 4575	Email: sharon.mt.ha@hktdc.org
Katy Wong	Tel: (852) 2584 4524	Email: katy.ky.wong@hktdc.org
Jane Cheung	Tel: (852) 2584 4137	Email: jane.mh.cheung@hktdc.org

Hong Kong International Medical and Healthcare Fair

Kelly Shek	Tel: (852) 2584 4537	Email: kelly.yt.shek@hktdc.org
Clayton Lauw	Tel: (852) 2584 4472	Email: clayton.y.lauw@hktdc.org

Media Room: http://mediaroom.hktdc.com

About HKTDC
The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.

Olympus Appoints New CEO

Names Bob White Representative Executive Officer, President, Chief Executive Officer and a new Director candidate

Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, today announces the appointment of a Chief Executive Officer (CEO) aimed at accelerating its ongoing transformation efforts in the medtech space.

The Board of Directors has decided unanimously to appoint Bob White, a former Executive Vice President and President, Medical Surgical Portfolio for Medtronic, as a successor to Yasuo Takeuchi, Olympus’ Director, Representative Executive Officer, President and CEO, effective June 1, 2025. Bob will also be proposed as a candidate for election to the Board at Olympus’ General Meeting of Shareholders scheduled to be held in June 2025.

“We are pleased to name Bob to this pivotal leadership role. He possesses a wealth of experience garnered from his tenure at various esteemed organizations within the medical technology sector. I look forward to welcoming him as a leader who will bring extensive knowledge and expertise to the company.” said Yasuo Takeuchi. “Over the course of his career, Bob has demonstrated exceptional leadership in driving both transformative growth and strategic initiatives. I am truly pleased that he is bringing this profound expertise and insight to Olympus.”

Comment from Bob White
“I am truly honored and grateful for the trust placed in me by the Board of Directors and the Nominating Committee. Olympus is an exceptional company, known for its market-leading solutions, cutting-edge technology, and remarkable people. I’m excited to bring my experience to the table and contribute to the company’s ongoing success and growth. I’ve long admired Olympus for its rich Japanese heritage, outstanding products, and unwavering commitment to serving the needs of both clinicians and patients.”

Bob most recently served as Executive Vice President and President, Medical Surgical Portfolio for Medtronic until April 2024. Before then, he was Senior Vice President and President of Medtronic Asia Pacific, based in Singapore where he had responsibility for APAC as well as Japan. During his tenure at Covidien, he held the positions of President of Emerging Markets and President of Respiratory and Monitoring Solutions. He has seen numerous innovation programs and led several R&D initiatives and M&A transactions within complex business portfolios. His close engagement with the market and customers has enabled him to maintain a strong understanding of physician needs.

Prior to joining Medtronic, Bob held leadership positions at GE Healthcare, Merge Healthcare and Healthcare Division, IBM. Throughout his career in the medtech industry, he has played a pivotal role in improving the lives of patients around the world through the transformation of healthcare delivery.

In order to select and recommend the best candidate for the next CEO, the Nominating Committee engaged a leading executive search firm and formed an Advisory Search Committee in November 2024. After a comprehensive and rigorous search process, Olympus determined that Bob is the ideal leader among a strong pool of internal and external candidates. Bob possesses the skill set necessary to guide the next phase of Olympus’ transformation, including quality and regulatory initiatives.

Bob holds a bachelor’s degree in marketing from Cleveland State University and an MBA in finance from Case Western Reserve University, USA. He currently resides in Colorado and will be located in Olympus global headquarters in Tokyo, with his wife.

About Olympus

At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global X account: @Olympus_Corp.

Media contact:
Mail: Global-Public_Relations@olympus.com

Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD). The study is led by Dr. Alireza Faridar and Dr. Stanley Appel at the Houston Methodist Neurological Institute (Houston, TX) with funding from The Peggy and Gary Edwards Endowment Fund. Study patients received subcutaneously administered CTLA4-Ig, followed by a 5-day course of low-dose IL-2 every four weeks, for a total of 22 weeks of dosing and follow-up. The study aims to enroll up to 10 patients, and these interim results include data from the first 5 patients with mild to moderate FTD who have completed the full course of treatment.

Dr. Arun Swaminathan, Coya’s Chief Executive Officer followed: “The results thus far are consistent with previously published encouraging data from an open-label investigator-initiated study of patients with ALS treated with low-dose IL-2/CTLA4-Ig. This interim data in FTD provides us further confidence of our approach to target and enhance Treg biology to address devastating neurodegenerative diseases including ALS and FTD”.

Previous biomarker data presented by the Company demonstrated that FTD patients exhibit a compromised immunosuppressive function of regulatory T cells (Tregs), along with increased peripheral levels of inflammatory cytokines and chemokines, dysregulation of monocytes, and systemic activation of the inflammatory cascade, supporting the critical role of the immune system in the pathophysiology of FTD.

One previous study showed that a cohort of 68 patients with FTD worsened by an average of 3.57 points over a 12-month period per the Clinical Dementia Rating – Frontotemporal Lobar Degeneration (CDR‐FTLD) scale (Knopman et al. Brain 2008; 131(11): 2957-2968). In addition, patients with FTD typically have shorter survival times and more rapid rates of cognitive and functional decline compared to patients with Alzheimer’s disease (Rascovsky et al. Neurology 2005; 65(3): 397-403).

Dr. Fred Grossman, Coya’s Chief Medical Officer stated: “We are excited with the results observed in this initial group of patients with this proof-of-concept study. We believe that the increase in Treg numbers and suppressive function, with subsequent anti-inflammatory biological activity still to be evaluated, underscores the potential for this low-dose IL-2/CTLA4-Ig combination to be further studied as a therapy for FTD, for which there are no currently approved treatments.”

Summary of Interim Study Results

Overall, treatment with low-dose IL-2 and CTLA4-Ig was well tolerated. All 5 patients enrolled in the first cohort completed the study and received the investigational treatment as planned. The most common adverse events were mild injection site reactions. No serious adverse events were reported.

Treg numbers and suppressive function increased after the first treatment cycle (p < 0.01 and p < 0.05, respectively, and remained at higher significant levels throughout the treatment period.

Clinical functional assessments were performed in all patients at pre-specified timepoints over the course of the study using validated tools, including the Clinical Dementia Rating – Frontotemporal Lobar Degeneration (CDR‐FTLD) scale, the Montreal Cognitive Assessment (MoCA) scale, and the Progressive Aphasia Severity Scale (PASS). Results of the functional tests show that, on average, these five FTD patients treated with low-dose IL-2 and CTLA4-Ig combination exhibited minimal to no cognitive decline over the course of the study, compared to pre-treatment values.

The Company intends to publish and/or present more comprehensive data in a future peer-reviewed meeting and/or publication.

About Frontotemporal Dementia

Frontotemporal dementia (FTD) refers to a group of neurodegenerative disorders characterized by altered behavior and language, with a progressive decline in executive function.1 FTD affects an estimated 30,000 Americans.2 FTD is categorized clinically into various subtypes; the main three include behavioral-variant frontotemporal dementia and two language variants, semantic dementia (also known as semantic variant primary progressive aphasia) and progressive non-fluent aphasia (also known as non-fluent variant primary progressive aphasia). It’s a presenile dementia, meaning it can occur in younger individuals, often between the ages of 45 and 64. The average age of onset is 58, with an average survival time of 7.5 years.1,2

References
1. Knopman et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 2008; 131(11): 2957-2968

2. Rascovsky et al. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 2005; 65(3): 397-403

About Coya Therapeutics, Inc.

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.

Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

COYA 302 is a combination treatment comprised of low-dose IL-2 and CTLA4-Ig is an investigational therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of Tregs and suppress the inflammation produced by activated monocytes and macrophages. Coya is developing COYA 302 for the treatment of fatal neurogenerative diseases characterized by chronic inflammation and Treg dysfunction.

For more information about Coya, please visit www.coyatherapeutics.com

Forward-Looking Statements

This press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements.

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; ; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Contact:
David Snyder, CFO
david@coyatherapeutics.com

CORE IRBret
Shapirobrets@coreir.com
561-479-8566

Media Contacts

For Coya Therapeutics:
Kati Waldenburg
media@coyatherapeutics.com
212-655-0924

A Decade of Olympus India’s Commitment to Community Welfare

Benefiting 7,000 Children Across 30 Schools with its CSR Initiatives

Olympus Medical Systems India Pvt. Ltd. (OMSI), an Olympus Group company, today announces the successful inauguration of newly constructed washrooms at eight government schools across major locations in India. This milestone is part of OMSI’s corporate social responsibility (CSR) initiative, the Water, Sanitation, and Hygiene (WASH) Program. By actively supporting community well-being and education through long-standing projects, OMSI and Olympus Corporation (Olympus), remain dedicated to supporting the next-generation education in India.

Inauguration Ceremony at Government Middle School, Aklimpur, in Sohna Block of Gurugram District of Haryana, India

The WASH Program, a decade-long CSR project by OMSI, focuses on enhancing school infrastructure by constructing and renovating washrooms to ensure that students—especially girls—have access to clean and safe sanitation facilities. This initiative addresses critical challenges in sanitation, hygiene, and child health that directly impact education. Several reports highlight that one in four girls in India drop out of school due to inadequate toilet facilities, underscoring the vital importance of this initiative for promoting gender equality and educational continuity.

Over its fiscal year which ended in March 2025, the 10th year since the program began, OMSI constructed washrooms in eight government schools across four major locations—Delhi NCR, Kolkata, Chennai, and Mumbai. —This initiative provides improved sanitation facilities for over 2,700 students and ensures better hygiene standards for the school communities. The inauguration for these schools took place in March 2025, attended by OMSI leaders, school headmasters, and other officials. Over the past decade, the company has contributed to creating hygienic learning environments for approximately 7,000 students across 30 schools through this program.

Nutrition kits handed over by Naoshi Kikumoto,MD, OMSI

Additionally, OMSI’s Olympus Arogya Bachpan (Disease-Free Childhood) Program, provided health check-ups, distributed nutrition kits, and held awareness sessions on essential topics such as personal hygiene and safety for approximately 450 students across two schools. This program, initiated in 2018, aims to improve student well-being through hygiene education, child safety awareness, and health check-ups, helping to combat malnutrition and instill lifelong healthy habits.

Since its establishment in 2009, OMSI has remained committed to enhancing health, hygiene, and awareness through these activities, positively impacting thousands of children across India and enabling them to pursue their education in a safe and hygienic environment.
“We at Olympus believe that every child deserves the opportunity to grow up healthy and to receive a quality education. Through our CSR programs, we are proud to contribute to a brighter, healthier future for children and communities across India,” said Naoshi Kikumoto, Managing Director, OMSI.

Together with Olympus, OMSI will continue advancing global corporate citizenship to make people’s lives healthier, safer, and more fulfilling across India and beyond.

Olympus’ Other CSR activities in India:
Beyond its ongoing efforts in areas of hygiene and sanitation, OMSI also played a crucial role in supporting India’s healthcare infrastructure. In its fiscal year which ended in March 2025, the company supported the Saairaam Cancer Foundation in Salem, Tamil Nadu, and JIPMER (Jawaharlal Institute of Postgraduate Medical Education and Research), Pondicherry, by donating a Laparoscopic System and contributing to ENT (ear, nose and throat) cancer screening initiatives, respectively. These efforts aim to enhance cancer awareness, early detection, and treatment in underserved regions.

During the COVID-19 pandemic, in its fiscal year ended in March 2021 and 2022, OMSI supported Civil Hospital Gurgaon, with Antigen Test Kits, Viral Transport Medium Kits, canopy tents for testing camps, and rental vehicles for transporting samples and lab technicians. The company also donated a fully equipped ambulance, solar lights and other essentials to support the Earth Saviours Foundation. Furthermore, OMSI focused on strengthening infrastructure at Primary Healthcare Centers (PHCs) in remote areas across the country. It also provided basic sanitation facilities at government hospitals in severely affected regions lacking such services.

About Olympus
At Olympus, we are committed to Our Purpose of making people’s lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit https://www.olympus-global.com/ and follow our global X account: @Olympus_Corp . Also visit LinkedIn page of OMSI.

For media inquiries, please contact:
Sanjana Grover
Olympus Medical Systems India Pvt Ltd
sanjana.grover@olympus.com
https://www.olympus.in/

Public Relations Group
Olympus Corporation
Global-Public_Relations@olympus.com
https://www.olympus-global.com/

Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com

analytica Vietnam 2025 Opens Tomorrow: The Leading Laboratory Exhibition Returns to Vietnam

analytica Vietnam 2025, Vietnam’s premier international trade fair for laboratory technology, analysis, biotechnology, and diagnostics, will officially open tomorrow at the Saigon Exhibition and Convention Center (SECC). Running from 2-4 April 2025, this highly anticipated exhibition promises to showcase groundbreaking innovations, cutting-edge technologies, and a dynamic conference program, bringing together over 300 exhibitors from 18 countries.

Endorsed by the Ministry of Science and Technology in Vietnam and supported by the National Agency for Science and Technology Information and Statistics (NASTIS), the Center for Science and Technology Information (CESTI), the Key Laboratory of Analytical Technology for Environmental Quality and Food Safety Control (KLATEFOS), VNU, the Federal Ministry for Economic Affairs and Climate Action of Germany, and the Association of Small & Medium Enterprises (Singapore), analytica Vietnam continues to grow as the most influential laboratory event in Southeast Asia.

In response to growing demand and expanding participation, analytica Vietnam introduces Hall A2 for the first time this year, adding 7,000 sqm of exhibition space in total, alongside the existing Hall A1. This expansion accommodates more exhibitors and innovations, reinforcing the event’s status as Southeast Asia’s leading laboratory exhibition.

A Platform for Global Collaboration in the Laboratory Sector

“The expansion with the new exhibition hall reflects our ongoing commitment to supporting the growth of the laboratory industry and fostering international collaboration,” said Mr. Michael Wilton, CEO of MMI Asia. “As Vietnam continues to emerge as a global hub for scientific and technological advancements, analytica Vietnam serves as a pivotal gateway for international companies seeking to enter this rapidly growing market, while providing local businesses access to world-class innovations.”

This year, analytica Vietnam 2025 will feature an impressive lineup of exhibitors, including global leaders in laboratory technology, biotechnology, and analysis. The German Pavilion, Singapore Pavilion, and China Pavilion will be the largest ever at the event, underscoring the growing international interest in the Vietnamese and Southeast Asian laboratory markets. Additionally, delegations from Vietnam, Laos, Cambodia, Thailand, and Malaysia highlight the exhibition’s expanding international reach and its role as a key facilitator of cross-border partnerships.

Pre-Show Press Conference

Before the official exhibition opening, a press conference was held on 31 March 2025 at the Crystal Palace Hotel, Ho Chi Minh City, where key industry players and media representatives gathered to discuss the significance of analytica Vietnam 2025.

Key speakers included:

– Mr. Vu Anh Tuan, Deputy Director, National Agency for Science and Technology Information and Statistics (NASTIS), who delivered the opening remarks, underscoring the event’s role in fostering technological innovation and international collaboration.

– Mr. Michael Wilton, CEO of MMI Asia, who provided insights into analytica Vietnam’s evolution, emphasizing its expanding international reach and growing influence within the industry.

– Representatives from leading exhibitors including ITS Vietnam, Waters, Kimteco Co., Ltd., and Hoa Viet Co., Ltd., who shared their experiences as returning participants, highlighting the strategic benefits of engaging with analytica Vietnam.

Complementing the pre-show activities, analytica Vietnam 2025 organized exclusive Lab Tours on 31 March and 1 April 2025, granting the exhibitors behind-the-scenes access to some of Ho Chi Minh City’s most advanced laboratory facilities. These tours provided a unique opportunity to observe state-of-the-art research, laboratory operations, and cutting-edge technological applications in real-world settings.

analytica Vietnam 2025 will feature a host of exciting new additions designed to engage attendees and provide valuable insights into the latest trends and innovations in the laboratory sector:

– LIVE LAB: A first for Southeast Asia, the LIVE LAB is a fully operational laboratory integrated into the exhibition floor. Visitors will have the opportunity to witness live demonstrations of laboratory processes, interact with experts, and explore real-world applications of the latest technologies.

– Startup Pavilion: Featuring emerging companies in the laboratory space, the Startup Pavilion will highlight new technologies and innovations shaping the future of the sector.

– Lab Design and Construction Forum: This forum will delve into sustainable and efficient laboratory infrastructure, offering insights from industry leaders on the future of lab design.

– Innovation Zone: A dedicated space showcasing breakthrough technologies transforming laboratory operations and industry practices.

– Exclusive Lab Tours: Specially curated behind-the-scenes tours of leading research and testing facilities in Vietnam will offer participants a deeper understanding of local industry advancements.

Additionally, the Academic Conference Program, one of the most anticipated segments of analytica Vietnam, will once again feature renowned thought leaders discussing critical industry trends, regulatory developments, and emerging research. Its strong reputation as a knowledge-sharing platform continues to attract top experts and professionals from around the world.

Join the Industry’s Most Influential Gathering

With only one day left until the grand opening, excitement is building for analytica Vietnam 2025. The exhibition is set to provide an unparalleled platform for industry professionals, researchers, and business leaders to explore the latest innovations, exchange knowledge, and establish meaningful collaborations.

Register now to be part of Vietnam’s premier laboratory technology event. For more details, visit www.analyticavietnam.com

About analytica Vietnam

analytica Vietnam is the premier trade fair for laboratory technology, analysis, and biotechnology in Southeast Asia. Organized by Messe München, the event brings together industry professionals, researchers, and policymakers to showcase the latest technologies,exchange knowledge, and foster business collaborations. analytica Vietnam features an exhibition, conference, pre-event laboratory tours, buyer-seller programs, and networking opportunities, providing a comprehensive platform for the laboratory and biotechnology industries in the region. The upcoming edition is set to take place from April 2 to 4, 2025 at the SECC – Saigon Exhibition and Convention Center. More details can be found at https://www.analyticavietnam.com/.

About analytica worldwide

Messe München is the world’s leading trade fair organizer for laboratory technology, analysis and biotechnology. The international network of exhibitions includes analytica, analytica China, analytica Anacon India & India Lab Expo, analytica Vietnam and analytica Lab Africa. Additional information about these exhibitions and their programs of events is available at.

About MMI Asia Pte Ltd

Established in 1992, MMI Asia is the wholly owned subsidiary and the regional headquarters of Messe München GMBH (MMG) and is one of the world largest and leading exhibition organizers. MMI Asia’s portfolio of events include editions of worldleading trade fairs from Munich – transport logistic & air cargo, analytica, ceramitec; as well as industry-specific events such as Glasstech and Fenestration Asia, Asia Climate Forum, and Singapore International Water Week. MMI Asia also provides consultancy in professional trade fair and conference management to government bodies, international trade and promotion organizations, and trade associations. For more information, please visit www.mmiasia.com

About Messe München

As one of the world’s leading trade fair organizers, Messe München presents the world of tomorrow at its about 90 trade fairs worldwide. These include twelve of the world’s leading trade fairs such as bauma, BAU, IFAT, electronica, and ISPO. Messe München’s portfolio comprises trade fairs for capital and consumer goods, as well as for new technologies. Together with its subsidiaries, it organizes trade fairs in China, India, Brazil, South Africa, Turkey, Singapore, Vietnam, Hong Kong, Thailand, and the U.S. With a network of more than 15 affiliated companies and almost 70 representations worldwide, Messe München is active in more than 130 countries. The more than 150 events held annually attract around 50,000 exhibitors and around three million visitors in Germany and abroad.

Exhibition Contact:

MMI Asia Pte. Ltd.
Daniel Shi
Exhibition Director
daniel@mmiasia.com.sg

Press Contact:

MMI Asia Pte. Ltd.
Joey Ng
Marketing Executive
joey@mmiasia.com.sg

Avantor Recognized with Two Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2025

Avantor Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, was recognized with two prestigious awards at the recent Asia-Pacific Biopharma Excellence Awards (ABEA) 2025. The recognition underscores Avantor’s commitment to providing high-quality biopharma manufacturing solutions, addressing logistics challenges and optimizing supply chain.

Specifically, Avantor was recognized for the ABEA:

Best Bioprocessing Supplier Award: Single Use Systems
Best Bioprocessing Supplier Award: Chromatography

Single-use solutions enhance flexibility and speed in biopharma manufacturing. As the only open-architecture provider, Avantor offers end-to-end design, manufacturing, and logistics support worldwide. With a diverse portfolio of chromatography resins and advanced production technologies, these solutions enable the rapid and scalable delivery of high-quality therapies.

Narayana Rao Rapolu, VP & GM, BPS AMEA, Avantor said, “We are honored by these two awards recognizing Avantor and our team’s contributions to advancing biomanufacturing. As biologics grow more complex, Avantor remains dedicated to providing innovative chromatography and single-use solutions that enhance flexibility, efficiency, and cost-effectiveness globally. Additionally, by leveraging our wide range of chromatography resins, process chemicals, and reagents, our application scientists, and customer support centers are able to provide total solutions that improve process efficiency.”

Rajesh Bhagwat, Director, Strategy & Marketing, BPS AMEA, Avantor said, “Avantor’s expertise in delivering customized, scalable solutions drives innovation in biopharmaceutical manufacturing. Our advanced chromatography resins, including PROchievA and J.T.Baker® Bakerbond®, provide unique selectivity for next-generation therapies across the Asia-Pacific region. This award reinforces our commitment to supporting customers at every stage, from small-scale development to large-scale production.”

Rajesh Bhagwat, Director, Strategy & Marketing, BPS AMEA, Avantor, receiving the Best Bioprocessing Supplier Award – Chromatography at ABEA 2025

Stephanie Chan, Head of Biopharma, SEA, Avantor, receiving the Best Bioprocessing Supplier Award – Single Use Systems at ABEA 2025

The Asia-Pacific Biopharma Excellence Awards (ABEA) recognizes exceptional Asian bioprocessing, biologistic, clinical trials and aseptic fill and finish experts, organizations and technologies. It celebrates outstanding achievements and innovations in the bioprocessing industry across the Asia Pacific region. The awards are judged by a panel of industry experts, and winners are selected based on their contributions to the advancement of the bioprocessing industry.

About Avantor

Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

Regional Media Contact:
Swati Chhabra
Manager – Corporate Communications, AMEA
Avantor
91-9958-404-334
swati.chhabra@avantorsciences.com

Global Media Contact:
Eric Van Zanten
Head – External Communications
Avantor
1-610-529-6219
eric.vanzanten@avantorsciences.com

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the dosing of the first participant with Parkinson’s disease (PD) in its Phase 1b clinical trial of GT-02287, the Company’s lead allosteric small molecule in development for the treatment of PD with or without a GBA1 mutation.

“Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with Parkinson’s disease. We look forward to continued enrollment and anticipate an interim analysis from the towards the end of 2Q 2025,” said Gene Mack, President and CEO of Gain Therapeutics.

The Phase 1b open-label, multi-center trial is designed to evaluate the safety and tolerability of GT-02287 in people with GBA1-PD and idiopathic PD. Secondary endpoints include pharmacokinetics, GCase modulation, levels of GCase substrates, and other biomarkers in plasma and cerebrospinal fluid. The trial will enroll up to 20 participants who will receive GT-02287 daily for three months. Interim data from the Phase 1b trial are anticipated at the end of 2Q 2025.

The Phase 1b trial follows Gain’s successful Phase 1 study in healthy volunteers completed during Q3 2024, in which GT-02287 demonstrated a favorable safety and tolerability profile as well as plasma and CNS exposures in the projected therapeutic range. Importantly, the Phase 1 study also showed significant target engagement of GT-02287 demonstrated by a statistically significant increase in glucocerebrosidase (GCase) activity that was >50%.

For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180

About GT-02287

Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is an allosteric enzyme modulator that restores the function of the lysosomal enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, and improved motor function and cognitive performance. Additionally, GT-02287 significantly reduced plasma neurofilament light chain (NfL) levels, an emerging biomarker of neurodegeneration.

Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggest that GT-02287 may have the potential to slow or stop the progression of Parkinson’s disease.

Gain’s lead program in Parkinson’s disease has been awarded funding support early in its development from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma exposure in the projected therapeutic range, CNS exposure, and target engagement and modulation of GCase enzyme.

Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.

Forward-Looking Statements

This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company’s current or future product candidates including GT-02287; expectations regarding the timing of results from a Phase 1b clinical study for GT-02287; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287; and the potential therapeutic and clinical benefits of the Company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2023 and Form 10-Q for the quarter ended September 30, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Apaar Jammu and Chuck Padala
ajammu@gaintherapeutics.com
chuck@lifesciadvisors.com

Media Contacts:

Russo Partners
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256

Giftify, Inc. Announces Smart Savings Solution for Popular GLP-1 Diabetes and Weight Loss Medications

Giftify, Inc. (NASDAQ:GIFT) (the “Company”), the owner and operator of CardCash.com and Restaurant.com, and a leader in the incentives and rewards industry, today announced that CardCash.com is offering consumers smart saving solutions for high-cost GLP-1 weight loss prescription medications like Ozempic (semaglutide) from Novo Nordisk and Zepbound (tirzepatide) from Eli Lilly.

CardCash.com, Giftify’s secondary gift card exchange platform, provides consumers with an innovative approach to reduce rising out-of-pocket expenses for increasingly popular GLP-1 medications. The strategy leverages discounted pharmacy gift cards from major retailers including CVS and Walgreens.

This program aligns with current national efforts to address healthcare affordability challenges. By providing practical tools to reduce prescription costs, CardCash.com is contributing to the ongoing public dialogue around making essential medications more accessible for all Americans, particularly as policymakers continue to explore comprehensive solutions to rising healthcare expenses.

Consumer feedback validates the financial impact of this approach. “As one Trustpilot reviewer, Corey Polk, shared, ‘I had significant savings on my Walgreens cards. I used it to buy Ozempic, and now I save about $30 a month.’ This is exactly what we aim for at CardCash — helping consumers find financial relief where they need it most,” said Carol Rosenblum, Marketing Manager at CardCash.com.

The platform’s strategy creates a multi-layered savings opportunity for medication purchasers. Users can combine CardCash’s discounted gift cards with manufacturer savings programs and prescription discount services like GoodRx and SingleCare. Additional cost reductions can be achieved through price comparisons between major pharmacy retailers including CVS, Walgreens, and Walmart.

This healthcare cost reduction initiative addresses growing market demand for GLP-1 medications such as Ozempic, Mounjaro, and Wegovy. By providing access to discounted gift cards that can be applied toward pharmaceutical purchases, CardCash extends Giftify’s value proposition into the healthcare sector.

“As prescription medication costs continue to rise, we’re leveraging our established gift card marketplace to create meaningful savings opportunities in healthcare,” said Ketan Thakker, CEO of Giftify, Inc. “This initiative aligns perfectly with our strategic focus on expanding our digital savings platforms into high-growth consumer markets. The increasing adoption of GLP-1 medications represents a significant opportunity to demonstrate the versatility and value of our business model.”

About Giftify, Inc.

Giftify, Inc. is a pioneer in the incentive and rewards industry with a focus on retail, dining & entertainment experiences, as the owner and operator of leading digital platforms, CardCash.com and Restaurant.com. CardCash.com is a leading secondary gift card exchange platform, allowing consumers and retailers to realize value by buying and selling gift cards at various scales. Its Restaurant.com is the nation’s largest restaurant-focused digital deals brand. Restaurant.com and our Corporate Incentives division connect digital consumers, businesses and communities offering thousands of dining, retail and entertainment deals options nationwide at over 184,000 restaurants and retailers. Restaurant.com prides itself on offering the best deal, every meal. Our gift cards and restaurant certificates allow customers to save at thousands of restaurants across the country with just a few clicks.

For more information, visit: www.giftifyinc.com and www.cardcash.com and https://www.restaurant.com.

Forward-Looking Statements

Press Releases may include forward-looking statements. In particular, the words “believe,” “may,” “could,” “should,” “expect,” “anticipate,” “estimate,” “project,” “propose,” “plan,” “intend,” and similar conditional words and expressions are intended to identify forward-looking statements. Any statements made in this news release about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the company. Accordingly, you should not place undue reliance on these forward-looking statements. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The company takes no obligation to update or correct its own forward-looking statements, except as required by law or those prepared by third parties that are not paid by the company. Statements in this press release that are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although Giftify, Inc. believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, Giftify, Inc. is unable to give any assurance that its expectations will be attained. Factors that could cause actual results to differ materially from expectations include the company’s ability identify a suitable business model for the corporation.

Investors Contacts:
IR@giftifyinc.com

Olympus Recognized on CDP’s “A List”, the Highest Rating in the Field of Climate Change

Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, today announced it has been recognized by CDP¹, an international environmental non-profit organization, as an “A List” company for fiscal year 2024. The A List rating is awarded to companies that demonstrate excellence in setting climate change-related targets and initiatives.

CDP evaluates major corporations and institutions around the world based on their responses to questions on climate change measures, water resource management, and environmental issues. In this year’s assessment, approximately 24,800 companies participated globally, including more than 2,100 Japanese companies.

As part of its Environmental, Social, and Governance (ESG) strategy, Olympus has designated “Carbon Neutral Society and Circular Economy” as a focal area. To contribute to the realization of a decarbonized future, Olympus established a target in May 2023 to achieve net-zero greenhouse gas emissions across its supply chain by 2040. In November 2023, Olympus received a net-zero² certification from the Science Based Targets initiative (SBTi)³, reinforcing its commitment to sustainability.

In addition, Olympus is accelerating its efforts to reduce greenhouse gas emissions by improving manufacturing processes, promoting energy-saving measures, and phasing power consumption at its facilities to renewable energy sources. Recognizing the importance of reducing the environmental impact across its entire supply chain, Olympus is working continuously to develop environmentally friendly products, enhance logistics efficiency, and set emission reduction targets in collaboration with suppliers. These initiatives support both the company’s sustainability goals and the broader global effort toward decarbonization.

For further details on Olympus’ sustainability initiatives, please visit the Sustainability page.

Comment from Yasuo Takeuchi, Olympus Director, Representative Executive Officer, and Executive Chairman and ESG Officer
“At Olympus, ESG principles are embedded in our corporate strategy as we work toward the realization of Our Purpose of making people’s lives healthier, safer and more fulfilling. Our recognition on CDP’s A list reflects our commitment to climate action and transparent environmental disclosure. We believe that contributing to the sustainable development and progress of the globe and society based on our founding spirit, by putting Our Purpose into practice, will allow Olympus itself to achieve sustainable growth and value creation.”

¹: CDP is a global non-profit that runs the world’s environmental disclosure system for companies, cities, states and regions. Founded in 2000, CDP pioneered using capital markets and corporate procurement to motivate companies to disclose their environmental impacts, and to reduce greenhouse gas emissions, safeguard water resources and protect forests. Fully TCFD aligned, CDP holds the largest environmental database in the world, and CDP scores are widely used to drive investment and procurement decisions towards a zero carbon, sustainable and resilient economy.

²: Net zero refers to reducing greenhouse gas emissions (Scopes 1, 2, and 3*) by at least 90% in line with the latest climate science (1.5°C scenario). Remaining emissions (less than 10%) must be offset using equivalent credits derived from carbon sequestration and removal (such as afforestation and CO2 capture and storage) to achieve balance.
*Scope 1: Direct greenhouse gas emissions by combustion of fuels in our sites.
Scope 2: Indirect greenhouse gas emissions from our sites use of electricity, heat or steam supplied by other companies.
Scope 3: Other, indirect emissions of greenhouse gas emissions (excluding Scope 1 and 2).

³: SBTi is an international initiative jointly established by the World Wildlife Fund (WWF), CDP, the World Resources Institute (WRI), and the UN Global Compact. The initiative encourages companies to set science-based greenhouse gas reduction targets that align with the goal of limiting global temperature rise to 1.5 degrees Celsius above pre-industrial levels.

Media contact:
Mail: Global-Public_Relations@olympus.com

Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS] https://www.olympus-global.com

World’s first high-standard negative-pressure isolation ward built with MiC technology completes historical mission

Laid solid foundation for modular design in isolation facility construction technology

Hong Kong’s healthcare engineering sectors have actively responded to the Hong Kong SAR Government’s efforts to promote advanced and modern construction technologies for fostering efficient building construction practices. In 2020, the industry adopted the innovative “Modular Integrated Construction” (MiC) technology, coupled with the “Multi-trade Integrated Mechanical, Electrical and Plumbing” (MiMEP) construction method, to construct the world’s first high-standard negative-pressure isolation ward module that could be assembled and deployed fast and easy. The module was repurposed for anti-epidemic use during the first wave of the COVID-19 pandemic that year. After the pandemic, the negative-pressure isolation ward module was put on public display at the CIC-Zero Carbon Park in Kowloon Bay to promote the MiC construction method. When the about two-year display ends in 2025, parts of the module will be recycled for purposes including reuse and further research. The project has demonstrated the immense potential of innovative engineering technologies in serving public health needs and laid a solid foundation for modular design in constructing infectious disease isolation facilities.

The engineering sector in Hong Kong putting all heads together, applying innovative thinking and technologies, contributed to the fight against the COVID-19 pandemic raging in 2020. It took the industry only four months, starting from initial sketching to completing the project, to deliver in May 2020 a negative-pressure isolation ward meets hospital-grade standards, the first of its kind globally and was later hailed as the “Hong Kong version of Huoshenshan Hospital.” The facility exemplified the professionalism, innovative spirit, and rapid crisis response capabilities of Hong Kong’s engineering sector. Moreover, it has provided a significant reference model for the concerned global community in addressing similar events.

The project used advanced MiC technology, plus the MiMEP construction method, which together significantly enhanced construction efficiency, shortening the entire construction cycle to just about a month. MiC technology enabled close to 80% of the construction process to be prefabricated in factories before being transported to the site for rapid assembly, adjustment, and testing. The approach not only drastically reduced on-site construction time, but also ensured high-quality standards and sustainability. Rigorous ventilation tests verified that the isolation ward could provide an effective negative-pressure environment, efficiently blocking the spread of highly infectious airborne viral particles. A distinctive feature of the design is it does not rely on a centralised air conditioning system with extensive external ventilation ducts. Instead, the MiMEP system’s built-in ventilation and air conditioning provide a self-sufficient airflow design, effectively controlling infection. Given her limited land resources, Hong Kong needs designs that can fit into small spaces, and the project was then a “highly condensed design” unprecedented in the world.

Ir Prof P L YUEN, Past President of the Hong Kong Institution of Engineers (HKIE), Past Vice President of the United Kingdom Chartered Institution of Building Services Engineers (CIBSE), and Chairman of the Hong Kong Branch of the United Kingdom Institute of Healthcare Engineering and Estate Management (IHEEM), said, “Inspired by the country’s ‘Huoshenshan’ project at the time, we began exploring how to construct high-standard isolation wards for limited spaces. The design required interlocking double-door control to precisely regulate airflow. To ease transportation, using the dimensions like those of a standard shipping container in our blueprint was an ideal option. By integrating MiC and MiMEP construction methods, we achieved a self-sufficient ventilation and air-conditioning design for the ward, matching with a compact electrical and mechanical module to supply its power and other engineering services demand. That innovative design was also the world’s first at the time.” Prof Yuen also shared this design with fellow engineers, fostering collaboration to construct more suitable isolation facilities.

Professor Yuen added, “The successful project shows that engineering innovation has a vital role to play in addressing public health challenges. While this project has fulfilled its historical mission, it is not the end. I hope it will encourage wider adoption of the proven method, novel and efficient, in other advanced building projects, which the Government is keen to promote. Furthermore, I hope it will inspire more local engineers to embrace innovation and technology, and together show and tell the many success stories of Hong Kong engineering.”

The design of the high-standard negative-pressure isolation ward features a self-sufficient airflow system enabled by the MiMEP construction method, that does not require a centralised air-conducting system with extensive external ventilation ducts. The built-in ventilation and air-conditioning system can effectively control infection by creating the necessary airflow path in the ward. Picture shows Prof Yuen conducting a smoke test showing air only flowing in one direction into the ward or being extracted through the ventilation system.

Rigorous ventilation tests verified that the high-standard negative-pressure isolation ward can provide a high-quality negative-pressure environment, effectively blocking the transmission of highly infectious airborne particles to outside occupying areas.

After the pandemic, the high-standard negative-pressure isolation ward module was put on an about two-year public display at the CIC-Zero Carbon Park in Kowloon Bay to promote the “Modular Integrated Construction” (MiC) method. When the display ends in 2025, some components of the module will be recycled for purposes including reuse and further research.

In addition to the double interlocking door control systems installed at the entrances to regulate airflow, the high-standard negative-pressure isolation ward is equipped with ultraviolet (UV) disinfection dual-door pass-through boxes to give patients convenience access to external supplies while minimising the need for medical staff to enter and exit the ward, as such reduce viral transmission risks.

The design of the ward eliminates the need for extensive external ventilation ducts or a centralised air-conditioning system. Instead, it utilises the self-sufficient ventilation and air-conditioning system coming with the MiMEP construction method that ensures a controlled only-into-the-ward airflow to effective prevent infection transmission.

About Ir Prof P L YUEN
Ir Prof P L YUEN is a professional engineer of 40 years in the healthcare engineering sector in Hong Kong. Early in his career, he worked in government departments, where he was responsible for construction, operation and maintenance of hospitals. Currently, he oversees the design and management of hospital engineering facilities within public healthcare institutions. Additionally, he leads the environmental and energy sustainability initiatives of both existing and planned hospitals, as well as hospital expansion projects across Hong Kong.

On combating the COVID 19 pandemic, armed with years of experience in research, design and construction of hospital ventilation system facilities, he was able to timely innovate and turn hospital wards into negative-pressure wards, including the community treatment facility at AsiaWorld-Expo, to meet the urgent need for public medical isolation facilities. During the epidemic, he was Government appointed Chairman of the Working Group on Implementing the Requirement on Air Change or Air in Dine-in Purifiers Restaurants that helped more than 18,000 eateries in Hong Kong improve ventilation in a few months, contributing to pandemic control in the community. Early in his career, he was invited by WHO and UNOPS to be their expert advisor and had travelled several times to Indonesia to offer technical guidance on how to build isolation wards across public hospitals there.

Ir Prof YUEN is the past President of the Hong Kong Institution of Engineers (HKIE), the current Chairman of the Engineers Registration Board in Hong Kong, the Hong Kong Branch Chairman of the United Kingdom Institute of Healthcare Engineering and Estate Management (IHEEM) and the past Vice President of the United Kingdom Chartered Institution of Building Services Engineers (CIBSE). In 2023, he was re-elected as Deputy Chair of the International Engineering Technologists Agreements (IETA) and was elected as Chair of the Seoul Accord. He is also a member of the Executive Committee of the International Engineering Alliance (IEA). An active participant in the work of international professional organisations and platforms, he has contributed much to consolidating the professional standard and promoting mobility of the engineering sector. He was bestowed Fellowship by the Energy Institute (EI) UK and received the Lifetime Achievement Award from IHEEM UK, and recently the Gold Medal, the highest honour, from UK CIBSE. He has been a Council member of the China Hospital Association’s Architectural Research Branch for close to two decades. In 2020, for his outstanding contribution to the fight against COVID-19, Ir Prof YUEN was presented the “Chief Executive’s Commendation for Community Service” by the Hong Kong SAR Government.